Home › Therapeutic areas › Immunology › Systemic Sclerosis
Systemic Sclerosis (12 companies)
Companies with an active program in Systemic Sclerosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $28.6M | 8 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 2 | Phase 2 | $280M | 8 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 2 | Phase 1 | $304M | 9 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | 1 | Phase 2 | $10.6M | 4 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $224M | 10 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 1 | Approved | $3.97B | 9 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | $124M | 8 |
| QNRX | Quoin Pharmaceuticals | DermatologyImmunology Rare | 1 | Phase 2 | $257M | 4 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $87.8M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
| ZURA | Zura Bio | DermatologyImmunology Rare | 1 | Phase 2 | $394M | 5 |
No companies match.